Immuneering-color-logo-CMYK_Resized.jpg
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
03 févr. 2025 16h05 HE | Immuneering Corporation
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
29 janv. 2025 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with...
1
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
07 janv. 2025 07h00 HE | Immuneering Corporation
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
05 déc. 2024 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
03 déc. 2024 22h38 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines.jpg
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
02 déc. 2024 07h30 HE | Revolution Medicines, Inc.
Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial Phase 1/1b proof-of-concept for...
Revolution Medicines.jpg
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
27 nov. 2024 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Screenshot_2.jpg
Blue Star Foods Announces Stock Buyback Program for Up to $1.5 Million
26 nov. 2024 14h30 HE | Blue Star Foods Corp.
Miami, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated Environmental, Social, and Governance (ESG)...
Revolution Medicines.jpg
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
06 nov. 2024 16h02 HE | Revolution Medicines, Inc.
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a...